Virtual Alumni Event with Dr. Stephanie Morain - 4/28/2026

Value of the Information & Strength of the Argument

The talk provides valuable insights into the ethical complexities of pragmatic clinical trials, a topic of growing importance in evidence-based medicine. Morain’s argumentation is well-structured, using concrete examples to illustrate abstract ethical concepts. She effectively highlights the tension between the need for real-world evidence and the traditional protections for research subjects. Her discussion of the minimal risk standard is particularly valuable, as she clearly explains the two competing interpretations and their practical implications. She also introduces a novel framework for evaluating the ‘rights and welfare’ criterion, which is often vague. The talk is persuasive in arguing that current regulatory frameworks may be ill-suited for PCTs, and she calls for more nuanced approaches. However, the argumentation is primarily from her own perspective, and she does not deeply engage with counterarguments or alternative viewpoints, which limits the comprehensiveness of the analysis.

Scientific Rigor, Source Quality, Title Accuracy

Morain demonstrates strong scientific rigor by referencing specific trials (e.g., the laryngoscope trial, PREP-IT, Kaiser vaccine trial) and regulatory documents (e.g., the Belmont Report, OHRP guidance). She also mentions her own published work, such as a JAMA special communication, which adds credibility. However, she does not provide detailed citations for all claims, and some references are only mentioned in passing. The title accurately reflects the content, as it is a virtual alumni event with a discussion on research ethics. The talk is well-organized and stays on topic, with no significant digressions. The presence of a personal anecdote about her daughter’s condition is relevant and humanizes the need for CER, but it is not a source of scientific evidence.

The title accurately reflects the content: a virtual alumni event featuring Dr. Stephanie Morain discussing contemporary challenges in research ethics.

8/10

The speaker is a recognized expert in research ethics, with a PhD and endowed professorship. The talk is based on her own research and published work, and she references specific trials and regulatory frameworks. However, it is a single expert's perspective, not a systematic review, and some claims are not fully referenced in the video.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction by Travis Rieder, welcoming attendees and introducing Dr. Stephanie Morain.
• 02:00Dr. Morain begins her talk, outlining her background and the focus on pragmatic clinical trials.
• 05:00Presentation of three example trials: laryngoscope, PREP-IT, and influenza vaccine trials.
• 10:00Discussion of key attributes of pragmatic clinical trials, including embedded research and lack of consent.
• 15:00Ethical motivations for PCTs, illustrated by personal anecdote about her daughter's PFAPA condition.
• 20:00Introduction of ethical and regulatory challenges, focusing on informed consent and minimal risk.
• 25:00Deep dive into minimal risk standard, contrasting incremental risk and OHRP's perspective.
• 30:00Discussion of the 'rights and welfare' criterion and proposal for assessing meaningful patient decisions.
• 35:00Examples of decisions where patient input is or is not meaningful, such as laryngoscope vs. surgery.
• 40:00Conclusion and Q&A session, addressing additional challenges like data monitoring and equity.

• Belmont Report — Referenced as foundational to research ethics, distinguishing research from practice.
• OHRP Draft Guidance on SUPPORT Study — Discussed in relation to minimal risk determination for standard-of-care interventions.
• JAMA Special Communication on Incremental Risk — Morain and colleagues proposed the incremental risk standard for pragmatic trials.

• Belmont Report — Aligns with the talk's emphasis on distinguishing research from practice.
• OHRP Draft Guidance on SUPPORT Study — Discussed as a contrasting view on minimal risk, which the talk critiques.

• OHRP Draft Guidance on SUPPORT Study — OHRP's position that risks of standard-of-care interventions should be considered research risks when randomization changes treatment, which conflicts with the incremental risk standard.